UNION Therapeutics joins EuropaBio: Building a pipeline for inflammation and infectious diseases

Brussels, 14 April 2021 – EuropaBio is pleased to announce that UNION Therapeutics has joined as a corporate member. Founded in 2011, UNION Therapeutics is a Danish bio-pharmaceutical company dedicated to the discovery and development of novel medicines in the fields of both inflammatory and infectious diseases.

In joining EuropaBio, UNION will work together with members to push for a European industrial strategy that enables SMEs to validate and scale up high potential candidates more quickly, building on the ecosystem advances seen during the response to Covid-19.

EuropaBio Director-General Dr. Claire Skentelbery says “UNION Therapeutics illustrates the high potential within the European ecosystem for high impact products in a world with a string demand for rapidly accessible innovation. We will be working with UNION to showcase how Europe can unlock the talents from its SMEs.

Dr. Kim Domela Kjøller, Chief Executive Officer at UNION Therapeutics, added “We’re delighted to join EuropaBio to strengthen the collective voice of SME’s in the European biotech industry. We have initiated our collaboration with EuropaBio in our ambition to cover the unmet demand of Covid-19 treatments for vulnerable patient groups and are looking forward to working together in several capacities going forward.".

Download the full PRESS RELEASE below.